Compare TDOC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | CSTL |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.3M | 806.3M |
| IPO Year | 2015 | 2019 |
| Metric | TDOC | CSTL |
|---|---|---|
| Price | $5.94 | $24.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | $7.56 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 4.2M | 259.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | $344,229,000.00 |
| Revenue This Year | $1.19 | $2.42 |
| Revenue Next Year | $1.25 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.41 | 3.66 |
| 52 Week Low | $4.40 | $14.59 |
| 52 Week High | $9.77 | $44.28 |
| Indicator | TDOC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 45.99 |
| Support Level | $5.01 | $21.77 |
| Resistance Level | $8.91 | $26.44 |
| Average True Range (ATR) | 0.28 | 1.02 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 76.38 | 63.19 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.